This article is more than 5 years old. Information may no longer be current.
GSK's asthma, COPD drugs now available in US
Click Here to Manage Email Alerts
Two GlaxoSmithKline drugs approved by the FDA in 2014 for the treatment of asthma and COPD now are available in pharmacies nationwide, according to a press release.
Arnuity Ellipta, a fluticasone furoate inhalation powder, is a once-daily maintenance treatment for asthma in patients aged 12 years and older. The inhaled corticosteroid, available in 100 mcg and 200 mcg doses, reduces inflammation associated with asthma and helps to prevent and control its symptoms, the release said.
Incruse Ellipta, an umeclidinium bromide, is an anticholinergic intended for long-term, once-daily treatment of airflow obstruction in patients with COPD. The drug, available as a dry inhalation powder approved at 62.5 mcg, is administered through an Ellipta inhaler.
“These are the third and fourth respiratory products we’ve introduced since October 2013,” Jorge Bartolome, senior vice president of GSK’s US respiratory business unit, said in the release. “The Ellipta allows for a common inhaler platform across our inhaled therapies approved since 2013.”